Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$44.15
$44.17
$16.02
$45.23
$913.91M1.03704,539 shs1.24 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.52
+0.7%
$26.16
$23.14
$30.93
$3.64B0.461.47 million shs1.41 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$37.14
-0.6%
$36.43
$29.59
$60.37
$3.51B0.25837,463 shs1.20 million shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$34.55
-6.4%
$32.80
$16.01
$44.34
$3.81B0.96904,141 shs1.10 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00%0.00%0.00%0.00%0.00%
Perrigo Company plc stock logo
PRGO
Perrigo
0.00%-0.54%+0.42%-5.12%+3.78%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
0.00%-0.93%+4.59%-5.21%-0.75%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
0.00%-15.73%+6.31%-1.54%+83.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
4.6281 of 5 stars
2.13.04.23.53.01.72.5
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
4.2745 of 5 stars
3.53.00.03.82.92.50.6
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.0857 of 5 stars
3.41.00.00.02.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00
N/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0024.46% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.93
Moderate Buy$87.00134.25% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.75
Moderate Buy$47.3737.10% Upside

Current Analyst Ratings Breakdown

Latest ALBO, PRGO, ZLAB, and RARE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00
5/28/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
5/9/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.00
3/27/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.00
3/27/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$40.58M22.52N/AN/A$9.11 per share4.85
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.83$5.05 per share5.25$31.66 per share0.84
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$560.23M6.27N/AN/A$2.76 per share13.46
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.55N/AN/A$7.68 per share4.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.67N/A-4.16%8.93%3.87%8/1/2025 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest ALBO, PRGO, ZLAB, and RARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
5/6/2025Q1 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.37%N/AN/A 23 Years
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Latest ALBO, PRGO, ZLAB, and RARE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/A
6.32
6.23
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.40
2.24
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
94.25%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
6.90%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.50%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
13020.70 million19.27 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.93 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,29494.54 million89.34 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869110.33 million104.86 millionOptionable

Recent News About These Companies

Zai Lab Limited Unsponsored ADR stock logo
Zai Lab (NASDAQ:ZLAB) Shares Down 5.4% - Time to Sell?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Albireo Pharma stock logo

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.52 +0.20 (+0.74%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$26.46 -0.05 (-0.21%)
As of 06/20/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$37.14 -0.21 (-0.56%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$37.56 +0.41 (+1.12%)
As of 06/20/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$34.55 -2.38 (-6.44%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$34.24 -0.31 (-0.91%)
As of 06/20/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.